663 results about "Mouse Heart" patented technology

A mechanical circulatory support (MCS) system having an axial rotary blood pump with an impeller housing having a cylindrical pocket for receiving a magnet and closed by an end ring, requiring only a single circumferential weld and an axial weld. The impeller includes a shaft and one or more blades extending radially from the shaft. An inner and outer wall extend longitudinally from the shaft defining the pocket therebetween. A magnet array is positioned within the pocket and configured to be magnetically driven by an output shaft of a motor. The end ring is coupled to the end of the pocket opposite the shaft thereby encapsulating the magnet array within the pocket. Alignment holes may be provided within a floor of the pocket for orienting and balancing the impeller.

The transcatheter type artificial polymer heart valve comprises an integrated valve leaflet and a valve frame, the valve frame is of a hollow columnar grid structure, the valve frame is provided with a first end and a second end, the first end is provided with a plurality of stand columns at intervals in the circumferential direction, the integrated valve leaflet comprises a pipe body and a valve leaflet, the pipe body is provided with a third end and a fourth end, and the valve leaflet is arranged in the pipe body. The valve leaflets are arranged in the center of the third end, the valve leaflets are sequentially arranged in the circumferential direction, connecting grooves are formed in the connecting positions of the adjacent valve leaflets, and the connecting grooves are provided with through holes allowing the stand column to penetrate through; a connecting column is arranged on the outer wall of the pipe body, and a connecting hole matched with the connecting column is formed in the petal frame; when the integrated valve leaflet is arranged in the valve frame, the third end and the fourth end correspond to the first end and the second end respectively, the stand columns are inserted into the through holes, and the connecting columns are connected with the connecting holes in a one-to-one correspondence mode. Manual valve sewing is reduced, and the assembly efficiency is improved; stress concentration during opening and closing of the valve leaflet is reduced, and the performance of the valve is optimized.

The invention provides construction and application of a human pluripotent stem cell-derived heart organoid traditional Chinese medicine extract toxicity test chip. The chip comprises a plurality of micro-cell culture chambers and a micro-fluidic pore channel, heart organoid culture is carried out in the micro-cell culture room, culture media are added in the micro-fluidic channel to maintain the activity of the heart organoid, and traditional Chinese medicine extracts are added to evaluate the toxicity of traditional Chinese medicine. By simulating the reaction of the heart organ, the toxicity of the traditional Chinese medicine can be evaluated, the safety and effectiveness information about the traditional Chinese medicine can be provided, finally, the use of experimental animals can be reduced, and the animal welfare can be improved.

The present invention relates to a system for delivering an annuloplasty device for restoring a heart valve annulus from a dysfunctional configuration to a working configuration wherein the annuloplasty device is configured to expand from a preset configuration corresponding to the working configuration of the valve annulus, the system comprising a delivery device, a delivery device is configured to be removably coupled to an annuloplasty device, where the delivery device includes a structure configured to expand from a first configuration to a second configuration, where the second configuration is substantially equal to or greater than a predetermined configuration of the annuloplasty device.

The invention discloses a construction method and application of a mouse model for specifically tracing heart valve cells, and belongs to the technical field of animal model construction. The model construction method comprises the following steps: (1) constructing a Wid1-Cre hybrid mouse before inserting a Cre recombinase coding gene into a termination codon of a mouse Wid1 gene; and (2) hybridizing the Wid1-Cre hybrid mouse with the Rosa26-tdTomato homozygous report mouse, so as to obtain the double transgenic mouse which simultaneously carries the Wid1-Cre gene and the Rosa26-tdTomato gene. According to the invention, on the basis of the expression characteristic that Wif1 is only limited to a valve area in the heart, Wif1-Cre is constructed; according to the Rosa26-tdTomato mouse model, specific tracing of heart valve cells is achieved, and an important experimental tool is provided for mechanism research of heart valve diseases and development of therapeutic drugs.

Methods of using IL-2 fusion proteins to treat and / or prevent graft rejection, such as cardiac graft rejection, are disclosed.

A transient closed-loop system for cardiac pacing and / or defibrillator therapy for a subject includes a bioresorbable module configured to at least partially attach to an epicardial interface of the subject's heart for the cardiac pacing; at least one skin-interfaced module configured to attach to an outer surface of the subject's skin, wherein the bioresorbable module is in wireless communication with the at least one skin-interfaced module; and a control module in wireless communication with the at least one skin-interfaced module.

The application provides an application of a FAP-targeted CAR-T cell in preparation of a drug for treating cardiac fibrosis in a chronic phase of myocarditis. It is found in the application that FAP-specific CAR-T cells can effectively target cells expressing mouse FAP proteins, and the CAR-T cells can effectively eliminate cells expressing mouse FAP proteins after being activated, the chimeric antigen receptor T cells effectively reduce cardiac fibrosis in a chronic phase of myocarditis in mice, and restore the function after inflammatory injury. The application develops a CAR-T therapy for myocardial fibrosis caused by a chronic phase of myocarditis, and the chimeric antigen receptor T cells expressing a targeted fibroblast activation protein can recognize activated myocardial fibroblasts, and significantly reduce cardiac fibrosis after inflammatory injury and restore the function.

Provided is a method for screening myocardial therapeutic targets for ischemic heart failure by using single-cell sequencing, which method comprises the following steps: S1, sample preparation; S2, construction of a single-cell expression matrix; S3, cell quality control; S4, cell type annotation; S5, cell communication analysis; and S6, co-expression network analysis. The provided method for screening myocardial therapeutic targets for ischemic heart failure by using single-cell sequencing comprises performing single-cell sequencing on hearts of healthy mice and IHF mice, screening for cell types with significant differences in cardiac transcriptional profiles of the healthy mice and IHF mice, then exploring interaction characteristics of various types of cells in malignant fibrotic IHF hearts, revealing potential regulatory modules and pathways related to malignant myocardial fibrosis in single-cell expression data of IHF hearts, and performing screening to obtain Pdgfb and Tnfsf12 genes which can be used as therapeutic targets for treating myocardial fibrosis in ischemic heart failure.

Provided in the present disclosure are a model generation method and system, and a device, a storage medium and a program product. The generation method comprises: acquiring several ultrasound images of a target object and corresponding probing position information; extracting a contour feature point set of the target object from each ultrasound image, wherein the contour feature point set comprises a plurality of contour feature points; on the basis of the contour feature point set and probing position information corresponding to each ultrasound image, obtaining spatial position information of each contour feature point; on the basis of the spatial position information of each contour feature point, obtaining a target projection point of each contour feature point on a standard three-dimensional model corresponding to the target object; and on the basis of the spatial position information and target projection point of each contour feature point, calibrating the standard three-dimensional model to obtain a target three-dimensional model of the target object. The present disclosure automatically completes the quick construction of a three-dimensional cardiac model without manual intervention, thereby significantly shortening the time for constructing the three-dimensional cardiac model before surgery.

The invention discloses an extraction method of safflower leaf exosome-like nano-vesicles and application of the safflower leaf exosome-like nano-vesicles in preparation of drugs for preventing and treating adriamycin-induced cardiotoxicity, fresh safflower leaves are taken and cleaned, a PBS solution is added for crushing and filtering, filtrate is collected and continuously centrifuged, supernate is taken and subjected to ultracentrifugation, precipitates are collected after centrifugation, and the safflower leaf exosome-like nano-vesicles are obtained; and filtering and sterilizing by using a filter membrane to obtain the safflower leaf exosome-like nano-vesicles. The carthamus tinctorius leaf exosome-like nano-vesicles can significantly improve the heart function of doxorubicin-induced cardiotoxic mice; myocardial injury induced by doxorubicin can be repaired, and myocardial fibrosis induced by doxorubicin can be inhibited; the content of a myocardial injury marker lactic dehydrogenase in body serum can be reduced, a new treatment strategy is provided for preventing and treating adriamycin-induced cardiotoxic diseases, and the application prospect is good.

Systems and methods for powering and controlling implantable heart pumps are provided. An example system may include an external controller housing for housing a processor programmable to control an implantable heart pump, a battery housing removably attachable to the external controller housing for housing battery cells to supply power to the implantable heart pump, a button connected to the battery housing, and a latch extending from the button to a latch protrusion. The button may be biased away from the battery housing in a locked position. In the locked position, the latch protrusion may engage with a latch receiver of the external controller housing to lock the external controller housing to the battery housing. The button may be depressed toward the battery housing to cause the latch protrusion to disengage from the latch receiver to permit the battery housing to be detached and removed from the external controller housing.

The invention belongs to the technical field of heart organ chips, and provides a heart organ chip optimization method based on mechanical matching, which is used for optimizing a double-layer substrate in a heart organ chip, a strain sensor and an electrophysiological electrode. A double-layer substrate in a heart organ chip, a strain sensor and an electrophysiological electrode are optimized, and the method comprises the steps that for the double-layer substrate simulating an extracellular matrix and an epicardium, the Young modulus is reduced by controlling phase change of tetradecane, introducing pores into polydimethylsiloxane and improving the cross-linking ratio of the polydimethylsiloxane; a strain sensor and an electrophysiological electrode based on carbon nanotube-polydimethylsiloxane are integrated into a double-layer substrate, and the Young modulus of the strain sensor and the Young modulus of the electrophysiological electrode are matched with the Young modulus of the double-layer substrate. The problem that the Young modulus of the substrate and the sensor material is too high is avoided, and mechanical matching among the soft myocardial tissue, the sensor and the substrate is achieved.

The present disclosure provides an interference mitigation cartridge for cardiac vibrational waves. The reduction box comprises an upper end face, side faces, a bottom face and a box body inner cavity defined by the upper end face, the side faces and the bottom face. The impedance wave-absorbing layer on the upper end surface comprises a carbon fiber epoxy layer, a silica gel carbon powder layer and a porous silicone rubber layer of which the impedance values are gradually reduced from large to small, and a through hole is formed in the center of the impedance wave-absorbing layer; the through hole penetrates through the upper lining layer to form an upper inner layer facing the inner cavity of the box body; the damping resonant cavity is formed after a gap between the lower surface of the porous silicon rubber layer and the upper surface of the upper lining layer is sealed at the side edge; the input vibration acquisition plate is embedded into a groove which is sunken downwards from the upper surface of the impedance wave-absorbing layer and is used for receiving and conducting input vibration containing heart vibration waves and environmental interference waves; and the vibration wave sensor is connected with the lower surface of the input vibration acquisition plate through a magnetic connecting piece, is arranged in the inner cavity of the box body and is used for receiving heart vibration waves.

Provided is a magnetic thin film robot, which comprises a cardiac outer wrapping film module and a control module connected to each other. The cardiac outer wrapping film module comprises a non-magnetic supporting part and a magnetic driving part, and the non-magnetic supporting part and the magnetic driving part are mutually coupled. The control module comprises a patch-type magnetic field generator and a power supply assembly connected to each other, and the magnetic field generator in vitro corresponds to the magnetic driving part in vivo in terms of space. A magnetic field is generated through the control module, and the magnetic field drives the cardiac outer wrapping film module to provide heart failure assistance.

The invention discloses application of a JMJD6-targeted reagent in preparation of a medicine for promoting myocardial cell proliferation. The medicine can promote myocardial cell proliferation after myocardial infarction and reduce the myocardial fibrosis scar area caused by myocardial infarction. AAV9 myocardial specific overexpression virus and JMJD6 myocardial specific knockout mice are utilized, and the positive effect of JMJD6 in promotion of P1 cardiac apex resection of newborn mice and regeneration and repair of injured hearts after myocardial infarction of adult mice is disclosed for the first time; the specific mechanism is that JMJD6 depends on the activity of histone demethylase, enrichment of active modification H4R3me2a and H3R2me2s in a PDK4 promoter region is removed, transcriptional expression of the H4R3me2a and the H3R2me2s is inhibited, an impaired heart energy substrate utilization mode is stimulated to be increased and converted from fatty acid oxidation energy supply to glycolysis oxidation energy supply, and then adult myocardial cell proliferation is effectively promoted. The regeneration and repair capability of the heart after myocardial infarction is greatly improved, and a new effective target spot is provided for clinical treatment of myocardial injury.

The invention discloses a recombinant adeno-associated virus vector for targeted delivery of VEGF-C (vascular endothelial growth factor-C) and application of the recombinant adeno-associated virus vector in promoting endocardial differentiation to treat coronary heart disease. The rAAV vector comprises transgene for coding VEGF-C protein or VEGF-C protein functional variant and a tissue-specific promoter operably connected to the transgene, wherein the tissue specific promoter is capable of driving the transgene to be specifically expressed in the heart endothelial cells. According to the treatment method developed by the invention, specific expression of the Vegfc gene in the heart is driven by using an ICAM2 promoter with targeting to endothelial cells, and a remarkable curative effect is shown in a myocardial infarction model mouse. The therapeutic scheme provides a new effective strategy for intervention and treatment of myocardial infarction and chronic heart failure, and has the advantages of high safety, long gene expression duration, extremely low immune response to a host and the like.

The invention discloses application of 9 ''-salvianolic acid B monomethyl ester in preparation of a medicine for treating ischemic heart disease, and belongs to the technical field of biological medicine. The CAS number of the 9 ''-salvianolic acid B monomethyl ester is 1167424-31-8, the ischemic heart disease refers to myocardial injury induced by heart ischemia reperfusion, and the invention further provides a pharmaceutical composition or a small molecule injection preparation. Animal experiments show that 9 ''-salvianolic acid B monomethyl ester is exogenously injected to relieve myocardial injury of a mouse and improve the heart function of the mouse, and it is proved that the medicine containing 9''-salvianolic acid B monomethyl ester can improve the ischemic heart disease, especially myocardial injury caused by heart ischemia reperfusion, and has a good application prospect. The invention provides potential drug selection and research direction for preventing and treating ischemic heart disease, and has important clinical application value.

According to the multifunctional heart color ultrasound acoustic contrast examination device, the stirring mechanism is arranged in the cylinder, and the sealing mechanism and the mixing mechanism are integrated on the stirring mechanism, so that the efficiency and the sealing reliability in the contrast agent stirring process are remarkably improved. Wherein the mixing mechanism is fixedly connected to the outer wall of the stirring shaft and can drive the stirring plate to efficiently stir in multiple directions when the stirring shaft rotates, so that a contrast agent and gas can be fully mixed to generate mixed liquid with uniform and stable microbubbles, and the imaging quality and diagnosis accuracy of heart color ultrasound acoustic contrast examination are improved.

The invention relates to the field of biological medicine, in particular to application of S100A9 in treatment or detection of diabetic cardiomyopathy. The research finds that the expression of S100A9 in the heart tissue of a diabetic cardiomyopathy mouse is obviously increased. Overexpression of the S100A9 can aggravate myocardial injury and cardiac dysfunction, and inhibition of expression or activity of the S100A9 can improve illness conditions. Both the S100A9 inhibitor paquinimod and the macrophage scavenger chlorophosphonate liposome can reduce the concentration of S100A9 in serum, relieve cardiac enlargement and myocardial fibrosis and recover the left ventricular ejection fraction. In addition, the S100A9 can be used as a marker for detecting the diabetic cardiomyopathy, and related detection products can reflect the severity of the illness state by detecting the expression quantity of the S100A9 in tissue cells or body fluid. The invention provides a new target spot, medicine and detection means for treatment and detection of diabetic cardiomyopathy.

The present invention provides a method for providing information on an M-mode ultrasound image implemented by a processor and device using same, the method comprising the steps of: receiving an M-mode ultrasound image of a subject; segmenting a plurality of cardiac tomographic regions within the M-mode ultrasound image by using a segmentation model that is trained so as to segment the M-mode ultrasound image into a plurality of cardiac tomographic regions; and determining measurements for the plurality of segmented cardiac tomographic regions.

Systems and methods for delivering a docking device configured to receive a prosthetic valve are disclosed. A system can include a delivery catheter and a pusher device disposed in the delivery catheter and a docking device comprising a plurality of turns when in a coiled shape and having a proximal end portion and a distal end portion opposite the proximal end portion, where a retrieval line extends through a central lumen of the pusher device and is coupled to the proximal end portion of the docking device. The docking device is configured to move between a straightened shape when the docking device is arranged within the delivery catheter and the coiled shape after the docking device is pushed out of the docking device by the pusher device.

A valve implant includes an occlusive assembly and a frame coupled to the occlusive assembly. The frame transitions from a collapsed state to an expanded state about a central longitudinal axis and transitioning from the collapsed state to the expanded state causes a proximal end of the frame to expand radially outward from the central longitudinal axis. The valve implant further includes an outer sheet supported on a proximal portion of the frame. The occlusive assembly is supported on a distal portion of the frame such that the inner sheet extends about the central longitudinal axis and an annular opening is defined between the outer sheet and the inner sheet when the frame is in the expanded state.

The invention provides application of a DDX3X inhibitor in preparation of a medicine for treating myocardial fibrosis, and relates to the technical field of biological medicines. The invention relates to an application of a DDX3X inhibitor in preparation of a medicine for treating myocardial fibrosis. The invention proves that the myocardial cell fibrosis can be inhibited after the DDX3X is knocked down or knocked out, and the DDX3X inhibitor can interfere with the occurrence and development of mouse cardiac fibrosis and improve the cardiac function, thereby prompting that the DDX3X serving as the target of the anti-fibrosis medicine has a good medical transformation prospect, and further providing a research basis for preparing the anti-cardiac fibrosis medicine.

A retrieval device for retrieving a previously implanted device from a native valve of a patient's heart includes one or more retrieval components. The retrieval components include one or more of a device securing member, a device actuation member, and a clasp capturing member. The securing member is configured to attach the retrieval device to the previously implanted device. The actuation member engages the previously implanted device to move the previously implanted device from a closed configuration to an open configuration. The clasp capturing member is configured to attach to a clasp of the previously implanted device.

The invention provides an application of a CGRP inhibitor in preparation of a medicine for treating myocardial infarction or heart failure, relates to the technical field of biomedicine, and has the technical key points that the invention provides the CGRP inhibitor Rimegepant and provides an effect of the CGRP inhibitor Rimegepant in myocardial infarction and heart failure, and the CGRP inhibitor Rimegepant can be used for preparing a medicine for treating myocardial infarction or heart failure. The myocardial infarction and / or heart failure model is constructed through left anterior descending branch coronary artery ligation. In-vitro experiments verify that the expression of the CGRP receptor protein in the heart of a mouse after heart failure is increased, and prove that the CGRP inhibitor Rimegeant can effectively inhibit the expression of the CGRP receptor protein, and further research is carried out, so that a potential treatment strategy is provided for drug research and development. The in-heart CGRP receptor inhibitor can obviously relieve the myocardial infarction and / or heart failure course of mice, and down-regulate the protein expression of the CGRP receptor at the same time.

The present application discloses an implant, a transcatheter constriction ring system and their applications for reducing the risk of detachment. The implant includes a tightening wire and a plurality of anchoring components. The anchoring component includes an anchor and a threading structure rotatably sleeved on the anchor. The anchor is used for anchoring into heart tissue, and the threading structure is used for connecting the tightening wire. Among them, after a plurality of anchoring components are arranged along the circumferential direction of the heart tissue, the tightening wire is connected to the threading structure, and the tightening wire is located on the same side of the plurality of anchors that are anchored into the heart tissue. In this way, it can be ensured that after the constriction ring is completed, the anchoring components in the middle part are less stressed and the stress is more uniform, avoiding the situation where the anchoring components are stressed greatly, reducing the risk of detachment of the anchoring components, and making the implant safer; at the same time, the acting force of the anchoring components on the heart tissue is reduced, reducing the risk of damage to the heart tissue. In addition, when the tightening wire is tightened to form a constriction ring, the tightening wire moves stably and smoothly, ensuring the stability of the constriction ring and good constriction effect.

Embodiments of the present disclosure provide a mobile electrocardiogram (ECG) sensor comprising an electrode assembly comprising electrodes, wherein the electrode assembly senses heart-related signals when in contact with a body of a user, and produces electrical signals representing the sensed heart-related signals. The ECG sensor further comprises a processing device, operatively coupled to the electrode assembly, the processing device to provide the sensed heart-related signals to a machine learning module trained to predict a twelve-lead QT interval (QTc) value from the mobile ECG sensor comprising less than twelve leads. The ECG sensor also comprises a housing containing the electrode assembly and the processing device.

The invention discloses a construction method and application of an animal model for evaluating cardiotoxicity of antitumor drugs, sodium carboxymethyl cellulose (CMC-Na) with extremely low cost is adopted to replace matrigel, a tumor-bearing mouse model with high stability can be constructed at low cost, and experimental verification shows that 4T1 cells are resuspended by using a 0.7% CMC-Na solution, and the tumor formation rate of subcutaneous inoculation reaches gt; 95%. The tumor microenvironment-mediated cardiac injury critical period is accurately captured, and the constructed tumor-bearing mouse model is the optimal tumor-bearing mouse model for evaluating the cardiotoxicity of an antitumor drug (adriamycin) in the tumor microenvironment in the third week after the mouse has a 50mm < 3 > tumor.

Example cardiac pump systems are disclosed. An example cardiac pump system includes a cardiac pump coupled to a console. Further, the console includes a first display including a first visual representation of a first parameter of the cardiac pump system. Further, the first display includes a first status indicator and a second status indicator corresponding to the first parameter. Further, the first display is configured to display the first status indicator when the first parameter satisfies a first condition, and wherein the first display is configured to display the second status indicator when the first parameter satisfies a second condition.